)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
PeptiDream
PeptiDream (4587) investor relations material
PeptiDream Q2 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2026 earnings summary12 Aug, 2026
Executive summary
Achieved strong clinical pipeline expansion with six new programs entering clinical development in H1 2026, reaching 19 active clinical programs and meeting full-year guidance early.
Transitioned to a global discovery and development company, focusing on expanding the clinical pipeline, asset creation, and financial discipline.
Maintained disciplined cost control and robust cash position, supporting continued R&D and infrastructure investments.
Radiopharma segment delivered solid commercial growth, with PET product revenue up 30% year-on-year and total segment revenue of ¥8,025 million.
Strengthened leadership with new executive appointments and enhanced sustainability initiatives.
Financial highlights
H1 2026 revenue was ¥9,226.9 million, up ¥683.2 million or 8% year-over-year.
Operating loss narrowed to ¥2,463.9 million, and profit attributable to owners improved to ¥1,999.4 million loss.
EBITDA loss improved to ¥1,409 million, and EPS improved to ¥(15.51) from ¥(16.40) YoY.
PET product revenue grew 30% year-on-year, led by Amyvid and FDG.
Drug Discovery and Development business revenue rose to ¥1,201.1 million (+58% YoY).
Outlook and guidance
FY2026 revenue guidance reaffirmed at ¥32 billion, with operating income forecast at ¥4.6 billion and net profit at ¥3 billion.
Confident in achieving ¥15 billion revenue for drug discovery/development and ¥17 billion for Radiopharma.
Additional upside possible from new partnerships and "plus alpha" strategic transactions not included in base guidance.
Cash position expected to strengthen further with new deals in FY26 and FY27.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from PeptiDream
- Clinical pipeline expansion, new modalities, and AI-driven efficiency fuel growth and innovation.4587
Jefferies Global Healthcare Conference 2026 - Q1 2026 revenue rose 12.6% and net loss narrowed, with strong FY2026 growth forecast.4587Q1 2026
- FY2025 revenue fell 60% to ¥18.5B; FY2026 targets ¥32B and 6–12 new clinical programs.4587Q4 2025
- Radiopharmaceutical and peptide pipeline advances, plus facility investments, fuel strong growth.4587Status Update
- Significant revenue decline led to a net loss, but radiopharmaceuticals showed growth.4587Q3 2025
- Revenue and net income fell, but radiopharma growth and guidance remain strong.4587Q2 2025
- Late-stage radiopharma pipeline and AI-driven discovery fuel growth and global partnerships.4587Investor Day 2024
- Record H1 2024 profit and revenue driven by Drug Discovery and Novartis deal expansion.4587Q2 2024
- FY2024 saw record revenue and profit growth, robust pipeline, and strong guidance for FY2025.4587Q4 2024
Next PeptiDream earnings date
Q3 202611 Nov, 2026
PeptiDream
Next PeptiDream earnings date
Q3 202611 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
PeptiDream Inc. is a Japan-based biotechnology company specializing in peptide-based drug discovery and development. The company utilizes its proprietary Peptide Discovery Platform System (PDPS) to identify and optimize peptide therapeutics for various medical applications. PeptiDream collaborates with global pharmaceutical companies to develop novel therapeutics across multiple disease areas. Its research and development efforts focus on peptide-drug conjugates, small-molecule drugs, and peptide-based imaging agents. The company is headquartered in Kawasaki, Japan, and its shares are listed on the TSE.